KHO931 treatment had an anti-tumor effect in CBZ-resistant cell lines. Quantitative PCR revealed that KHO931 down-regulated mRNA expression of the Cytoskeleton (CSK)-related protein family, which regulates G2/M transition. A CSK-related protein inhibitor or genetic knockdown of CSK-related protein significantly suppressed cell proliferation of DU145CR and PC3CR. We tested the efficacy of KHO031 for CBZ resistance in mice xenograft models. KHO931 inhibited xenograft tumor growth in monotherapy. In addition, KHO931 and CBZ had a synergic effect on DU145CR and PC3CR xenograft tumors (Fig. B & C) . These results suggest that KHO931 has potential for reprogramming CBZ-resistant CRPC.
MP81-07 IL-8 PROTECTS PROSTATE CANCER CELLS FROM GSK-3b-INDUCED OXIDATIVE STRESS THROUGH ACTIVATING THE MTOR SIGNALING PATHWAY
Yi Sun*, Lu Yang, Qiang Wei, Chengdu, China, People's Republic of INTRODUCTION AND OBJECTIVES: Both oxidative stress and inflammation play important roles in prostate cancer cell apoptosis or proliferation. However, the mechanisms underlying these processes remain unclear. Thus, we chose IL-8 as the bridge between inflammation and cancer cell oxidative stress-induced death and confirmed its connection with mTOR and GSK-3b.
METHODS: We overexpressed GSK-3b and observed the effect of GSK-3b on reactive oxygen species (ROS) and cell death induced by oxidative stress. Then, IL-8 was upregulated or downregulated to determine its impact on preventing cells from damage by GSK-3b-induced oxidative stress. In addition, we confirmed the role of mTOR in this process through its overexpression or knockdown. Realtime PCR, Western blotting, transcription, Cell Counting Kit 8, flow cytometry and other techniques were used.
RESULTS: IL-8 promotes prostate cancer cell proliferation and decreases apoptosis, while GSK-3b induces cell death by oxidative stress through the activation of the caspase-3 signaling pathway by increasing ROS. In addition, mTOR can also decrease the activation of the caspase-3 signaling pathway by inhibiting GSK-3b and thus decreasing ROS production. Moreover, the inhibitory effect of IL-8 on GSK-3b occurs through the regulation of mTOR.
CONCLUSIONS: The results of this study highlight the importance of GSK-3b, which increases the production of ROS and then induces oxidative stress in tumor cells, while IL-8 and mTOR attenuate INTRODUCTION AND OBJECTIVES: Olaparib is reported to have antitumor effects for castration-resistant prostate cancer patients with germline mutations in DNA repair genes. Our microarray data showed that simvastatin downregulated DNA repair genes in androgen independent prostate cancer PC-3 cells. In this study, we investigated the combination therapy with Olaparib and simvastatin for castration-resistant and taxane-resistant prostate cancer.
METHODS: Androgen independent PC-3, 22Rv1 and androgen dependent LNCaP human prostate cancer cell lines and PrSC human non-transformed prostate cell were used. We have developed androgen-independent LNCaP cells (LNCaP-LA) by making a trade of FBS for charcoal stripped-FBS gradually. Microarray analyses were performed, followed by Ingenuity Pathway Analysis. mRNA and protein expressions were evaluated by quantitative real-time PCR and Western blot analysis, respectively. To knockdown a candidate gene, cells were transfected with siRNA. Cell viability was determined by MTS assay and cell counts.
RESULTS: Simvastatin altered many gene expressions in PC-3 cells. Microarray data and Ingenuity Pathway Analysis showed that the number of differentially expressed genes was the biggest in the pathway of "Role of BRCA1 in DNA Damage Response" (Fig.1) . In the validation, mRNA levels of BRCA1, BRCA2, RAD51, BARD1, FANCD2, RFC3, RFC4, RFC5, MRE11A, FANCA and FANCG, which were listed in "Role of BRCA1 in DNA Damage Response", were decreased significantly by simvastatin in PC-3 cells. Simvastatin decreased the expressions of BRCA1, FANCD2, RFC3, MRE11A and FANCG in 22Rv1 cells, BRCA2, RAD51, BARD1, RFC3 and RFC5 in LNCaP-LA cells, respectively. On the other hand, the expressions of all these genes were not changed in androgen dependent LNCaP cells after treatment of simvastatin. Moreover, simvastatin increased the expressions of all these genes in PrSC. The reduction in BRCA1 and BRCA2 expressions following siRNA transfection increased cytocidal effects of Olaparib in PC-3 and LNCaP-LA cells. The combination of Olaparib and simvastatin further enhanced the inhibition of cell proliferation compared with treatment with either drug alone in PC-3, 22Rv1 and LNCaP-LA, but not in PrSC. Moreover, we developed 22Rv1 having acquired resistance to Cabazitaxel (22Rv1-CR). In 22Rv1-CR cells, simvastatin also decreased the expressions of BRCA1, BRCA2 and FANCA, and the combination of Olaparib and simvastatin further enhanced the inhibition of cell proliferation compared with treatment with either drug alone.
CONCLUSIONS: Simvastatin alters the expressions of many genes concerned with DNA repair in castration-resistant and taxaneresistant prostate cancer cells. The combination of PARP inhibitor and the drugs, which decrease the expressions of DNA repair genes, can potentially affect castration-resistant and taxane-resistant prostate cancer growth.
Source of Funding: none

MP81-09 NOVEL LNCAMPC STIMULATED LIF/LIFR PATHWAY PROMOTES METASTASIS AND SERVES AS THERAPEUTIC TARGET IN PROSTATE CANCER
Wei Zhang*, Xiaolei Shi, Rui Chen, Shancheng Ren, Yinghao Sun, Shanghai, China, People's Republic of INTRODUCTION AND OBJECTIVES: Recently more and more novel disease-associated lncRNAs have been discovered by largescale RNA-seq. We aimed to identify a novel lncRNA NR_046357.1, which was named lncRNA activated in metastatic PCa (lncAMPC), investigate its contributions to metastasis and progression of PCa, and evaluate its clinical significance for patients.
METHODS: First, the expressions of lncAMPC in primary tumor tissue and urine samples of patients with localized or metastatic PCa were compared. Then the biological capacity of lncAMPC in PCa was demonstrated both in vitro and in vivo. Next, the mechanism study was conducted to reveal the mechanisms underlying the functional role of lncAMPC in PCa metastasis and progression. Last, the antitumor effect of targeting lncAMPC-activated pathway was evaluated.
RESULTS: We observed that lncAMPC was highly expressed in primary tumor tissue and urine samples of patients with metastatic PCa, and its transcription was activated by androgen receptor. The lncAMPC promoted cell proliferation, viability, migration and invasion in vitro, and enhanced tumorigenesis and metastasis of PCa in vivo. In cytoplasm, lncAMPC upregulated the expression of LIF by competitively binding and then inhibiting the activity of miR-637. In nucleus, lncAMPC enhanced the transcription of LIFR by decoying histone H1.2 away from the upstream sequence of LIFR gene. Interestingly, the stimulated LIF/ LIFR expression by lncAMPC promoted metastasis and progression in PCa via activating the Jak1-STAT3 signaling pathway. On one hand, the subset of patients with LIF/LIFR high expression had the shortest biochemical recurrence-free survival. On the other hand, LIF inhibitor achieved significantly tumor suppression through inhibiting PCa tumor cells and activating T cells in tumor microenvironment.
CONCLUSIONS: Our findings indicate that lncAMPC plays a critical role in PCa metastasis and progression by synergistically activating LIF/LIFR-Jak1-STAT3 signaling pathway in cytoplasm and nucleus. We also demonstrate a novel therapeutic strategy for metastatic PCa using androgen deprivation drugs and LIF inhibitor together. Therefore, lncAMPC may have significant value as an
